ImpediMed Limited (IPDQF) Stock

About ImpediMed Limited

ImpediMed Limited is a medical technology firm that specializes in software solutions. The company is involved in the creation, production, and global distribution of sophisticated bioimpedance spectroscopy (BIS) equipment and its accompanying software applications, serving markets in Australia, North America, and beyond. Its principal offerings include: SOZO: A non-intrusive BIS device engineered for the evaluation of lymphedema and for tracking fluid levels in individuals afflicted with heart failure. SFB7: A single-channel, tetrapolar BIS instrument utilized to assess the body composition of healthy individuals. ImpediVET: Another single-channel, tetrapolar BIS device, tailored specifically for veterinary applications to measure fluid status and tissue characteristics in animals. ImpediMed primarily markets its advanced medical devices to healthcare institutions such as hospitals and clinics. The company was founded in 1999 and its headquarters are located in Pinkenba, Australia.

ImpediMed Limited (IPDQF) stock trades at $0.00 with a market capitalization of $6.91M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.37, reflecting a net loss over the last twelve months, price-to-book of 1.18, price-to-sales of 0.85. Over the past 52 weeks the stock has ranged between $0.00 and $0.04, and currently trades 100.0% below its 52-week high.

On profitability, ImpediMed Limited generates a return on equity (ROE) of -117.92% (negative, reflecting a net loss), return on capital employed of -70.68%, an operating margin of -144.54%, a net profit margin of -171.25%.

Official website: www.impedimed.com